华大基因
(300676)
| 流通市值：178.94亿 | | | 总市值：179.92亿 |
| 流通股本：4.16亿 | | | 总股本：4.18亿 |
| 利润表 |
| 报告期 | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 |
| 营业总收入 | 1,788,516,575.76 | 808,653,640.32 | 3,705,385,018.37 | 2,673,638,742.11 |
| 营业总成本 | 1,663,446,182.11 | 789,867,458.16 | 3,833,902,696.89 | 2,563,396,603.57 |
| 其他经营收益 | | | | |
| 营业利润 | 61,684,925.16 | -9,901,532.55 | -593,180,639.02 | -35,804,257.97 |
| 利润总额 | 58,530,571.2 | -10,780,950.95 | -602,338,675.12 | -46,022,331.27 |
| 净利润 | 47,779,923.37 | -9,926,845.8 | -637,805,702.62 | -26,230,892.14 |
| 每股收益 | | | | |
| 其他综合收益 | -106,772,981.58 | -64,368,684.39 | -79,730,511.73 | -37,070,538.01 |
| 综合收益总额 | -58,993,058.21 | -74,295,530.19 | -717,536,214.35 | -63,301,430.15 |
| 资产负债表 |
| 报告期 | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 |
| 流动资产: | | | | |
| 流动资产合计 | 5,686,768,707.93 | 5,812,819,284.56 | 6,150,082,324.56 | 6,530,214,262.62 |
| 非流动资产: | | | | |
| 非流动资产合计 | 5,534,688,599.45 | 5,532,241,666.88 | 5,599,746,165.99 | 5,771,163,022.43 |
| 资产总计 | 11,221,457,307.38 | 11,345,060,951.44 | 11,749,828,490.55 | 12,301,377,285.05 |
| 流动负债: | | | | |
| 流动负债合计 | 2,021,948,780.14 | 2,239,042,720.62 | 2,538,442,324.2 | 2,327,734,268.98 |
| 非流动负债: | | | | |
| 非流动负债合计 | 571,044,303.25 | 567,019,696.86 | 604,670,537.06 | 601,849,297.22 |
| 负债合计 | 2,592,993,083.39 | 2,806,062,417.48 | 3,143,112,861.26 | 2,929,583,566.2 |
| 所有者权益(或股东权益): | | | | |
| 归属于母公司股东权益合计 | 8,516,823,944.08 | 8,427,335,066.6 | 8,493,226,271.63 | 9,241,414,587.53 |
| 股东权益合计 | 8,628,464,223.99 | 8,538,998,533.96 | 8,606,715,629.29 | 9,371,793,718.85 |
| 负债和股东权益合计 | 11,221,457,307.38 | 11,345,060,951.44 | 11,749,828,490.55 | 12,301,377,285.05 |
| 现金流量表 |
| 报告期 | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 |
| 经营活动产生的现金流量: | | | | |
| 经营活动现金流入小计 | 1,677,035,212.54 | 781,153,933.17 | 3,912,274,414.18 | 2,438,290,803.86 |
| 经营活动现金流出小计 | 1,953,855,565.57 | 962,507,489.28 | 3,975,489,256.7 | 2,874,963,894.61 |
| 经营活动产生的现金流量净额 | -276,820,353.03 | -181,353,556.11 | -63,214,842.52 | -436,673,090.75 |
| 投资活动产生的现金流量: | | | | |
| 投资活动现金流入小计 | 3,262,547,665.89 | 1,732,714,828.1 | 6,090,703,333.63 | 4,754,090,112.22 |
| 投资活动现金流出小计 | 3,350,993,739.14 | 1,646,904,692.64 | 7,115,892,410.75 | 5,524,826,384.48 |
| 投资活动产生的现金流量净额 | -88,446,073.25 | 85,810,135.46 | -1,025,189,077.12 | -770,736,272.26 |
| 筹资活动产生的现金流量: | | | | |
| 筹资活动现金流入小计 | 33,825,689.76 | - | 640,160,215 | 640,160,215 |
| 筹资活动现金流出小计 | 96,839,662.95 | 40,773,473.28 | 490,301,688.77 | 460,115,581.24 |
| 筹资活动产生的现金流量净额 | -63,013,973.19 | -40,773,473.28 | 149,858,526.23 | 180,044,633.76 |
| 汇率变动对现金及现金等价物的影响 | -29,901,643.04 | -17,034,709.79 | -1,550,675.11 | 7,022,116.61 |
| 现金及现金等价物净增加额 | -458,182,042.51 | -153,351,603.72 | -940,096,068.52 | -1,020,342,612.64 |
| 期末现金及现金等价物余额 | 1,300,248,503.67 | 1,604,969,552.16 | 1,758,321,155.88 | 1,678,074,611.76 |
| 补充资料: | | | | |
| 现金及现金等价物的净增加额 | -458,182,042.51 | - | -940,096,068.52 | - |